RADEK SKODA to Aged
This is a "connection" page, showing publications RADEK SKODA has written about Aged.
Connection Strength
0.304
-
[Myeloproliferative neoplasms - Update on diagnosis and treatment]. Ther Umsch. 2019; 76(9):487-495.
Score: 0.041
-
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014 Apr 03; 123(14):2220-8.
Score: 0.029
-
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010 Mar 11; 115(10):2003-7.
Score: 0.022
-
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009 Feb 26; 113(9):2022-7.
Score: 0.021
-
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008 Dec; 93(12):1890-3.
Score: 0.020
-
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica. 2008 May; 93(5):706-14.
Score: 0.020
-
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008 Jan; 93(1):34-40.
Score: 0.019
-
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007 Jul 01; 110(1):375-9.
Score: 0.018
-
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006 Aug 15; 108(4):1377-80.
Score: 0.017
-
Identification of Hepatic-like EPO as a Cause of Polycythemia. N Engl J Med. 2025 May 01; 392(17):1684-1697.
Score: 0.016
-
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28; 352(17):1779-90.
Score: 0.016
-
Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol. 2000 Jun; 79(6):312-8.
Score: 0.011
-
Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020 04 30; 135(18):1548-1559.
Score: 0.011
-
Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. Ann Hematol. 2017 Mar; 96(3):393-404.
Score: 0.009
-
Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms. Mol Carcinog. 2017 02; 56(2):567-579.
Score: 0.009
-
Dkk3 levels in patients with myeloproliferative neoplasms. Thromb Res. 2014 Feb; 133(2):218-21.
Score: 0.007
-
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011 Mar 10; 117(10):2813-6.
Score: 0.006
-
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008 Feb 01; 111(3):1686-9.
Score: 0.005
-
The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. Br J Haematol. 1998 Sep; 102(5):1341-3.
Score: 0.003
-
[Immuneglobin-D-serum level with healthy test persons and patients with diseases of the respiratory tract (author's transl)]. Laryngol Rhinol Otol (Stuttg). 1978 Sep; 57(9):850-6.
Score: 0.003